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Ezetimibe in Combination With a Statin Does 
Not Reduce All-Cause Mortality
Akshar Y. Patela, Jayasree Pillarisettib, Joshua Marrb, James L. Vacekb, c
Abstract
Background: Although the ezetimibe-statin combination has been 
shown to reduce LDL cholesterol by 12% compared to a statin 
alone, its effect on hard clinical endpoints such as mortality is less 
certain. Prior trials evaluated this combination in highly select pop-
ulation groups, but impact on all- cause mortality in the general 
population has not been reported.
Methods: A total of 3,827 subjects who were prescribed either a 
statin (group 1) or the combination of statin with ezetimibe (group 
2) between January 1st, 2005 and January 1st, 2008 were studied. 
Socio-demographic and clinical variables and mortality records 
were analyzed. Univariate and stepwise multivariate logistic re-
gression analysis was performed to identify the impact of ezeti-
mibe on all-cause mortality, controlling for patient characteristics, 
selected cardiovascular diseases and risk factors, and medications.
Results: Group 1 (n = 2,909), and group 2 (n = 918) were similar in 
regards to most demographic variables, 152 patients died from any 
cause during the study period. There was no difference in all cause 
mortality between the groups. Hypertension, higher HDL-C and 
omega-3 fatty acid use were associated with ezetimibe use in this 
cohort of patients and were considered as covariates in the analysis. 
Patients on the drug combination did not experience lower mortal-
ity after controlling for covariates and other significant risk factors.
Conclusions: No significant mortality benefit was found with the 
use of ezetimibe in combination with a statin over use of a statin 
alone. Omega-3 fatty acid use and higher HDL-C demonstrated a 
substantial survival benefit.
Keywords: Ezetimibe; LDL; HDL; Mortality
Introduction
Ezetimibe is a cholesterol lowering medication that works 
by blocking enteric and biliary absorption of cholesterol, al-
though its exact mechanism of action and affect on various 
other body systems related to atherosclerosis are under de-
bate [1]. Approved in 2002, Ezetimibe in combination with a 
statin has been shown to reduce LDL cholesterol ((LDL-C)) 
15% more compared to a statin taken alone [2]. Ezetimibe 
as a monotherapy has been shown to reduce LDL-C by18 
% when compared to a placebo [2, 3]. Because the associa-
tion between LDL-cholesterol reduction and decreased car-
diovascular risk has been clearly established, ezetimibe was 
assumed to possess clinical efficacy and became routinely 
prescribed [4].
Although the effectiveness of ezetimibe in lowering 
cholesterol has been demonstrated in several studies, its 
clinical efficacy has been called into question following the 
ENHANCE trial (Ezetimibe and Simvastatin in Hypercho-
lesterolemia Enhances Atherosclerosis Regression) which 
showed that there was no difference in the carotid intima-
media thickness in patients taking simvastatin and ezetimibe 
compared to those on simvastatin alone, despite having re-
duced overall total cholesterol, LDL-C, triglycerides , and 
C-reactive protein [5].
Other studies that followed yielded conflicting results 
with SANDS (Stop Atherosclerosis in Native Diabetics 
Study) and VYCTOR (Vytorin on Carotid Intima-Media 
Thickness and Overall Arterial Rigidity) demonstrating a 
reduction in carotid intima-media thickness. However the 
ARBITER 6 HALTS trial (Arterial Biology for the Inves-
tigation of the Treatment Effects of Reducing Cholesterol 
6-HDL and LDL Treatment Strategies in Atherosclerosis) 
showed no improvement in intima-media thickness with the 
addition of ezetimibe. Further, the impact of ezetimibe on 
hard clinical endpoints such as mortality and cardiovascu-
lar events has not been proven till date [6-8]. Two studies 
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(SEAS: Simvastatin and Ezetimibe in Aortic Stenosis, and 
SHARP: Study of Heart and Renal Protection) that demon-
strated reduction in major cardiovascular events involved 
comparison of patients taking a combination of a statin plus 
ezetimibe versus those taking a placebo alone [9, 10]. The 
true clinical effect of ezetimibe can only be inferred by using 
a comparison group that takes a statin alone.
We therefore conducted a retrospective cohort study to 
compare differences in all-cause mortality between patients 
taking ezetimibe and a statin, and those on monotherapy 
with a statin alone.
Methods
A flowchart of cohort assembly can be found in Figure 1. 
The University of Kansas Hospital Mid-America Cardiology 
database of electronic patient medical records was used for 
this study. The study was carried out after obtaining approval 
from the human subjects committee and waiver of consent 
for data retrieval.
All social, demographic and clinical variables were ob-
tained from the electronic database. Baseline lipid values of 
all patients on a statin prior to initiation of ezetimibe were 
also retrieved.
Study population; Patients who were not diagnosed with 
dyslipidemia were excluded, and only patients who were 
prescribed a statin were included. Patients taking combina-
tion ezetimibe and a statin (group 1) were compared to those 
prescribed only a statin (group 2). In order to account for dif-
ferences in prescribing patterns due to the novelty of ezeti-
mibe, patients who were prescribed either medication before 
January 1st 2005 were excluded. There was a dramatic fall 
in ezetimibe prescriptions after articles with negative and in-
conclusive findings were published, therefore new prescrip-
tions after January 1st, 2008 were also excluded [5].
Follow-up: All patients were followed until January 
2009. Patients who were on either medication for at least 1 
year and died during this time period were noted.
Endpoint
The study’s primary endpoint was all cause mortality.
Statistical analysis
Continuous variables between the groups were compared us-
ing unpaired t tests or Wilcoxon two-sample tests depending 
Figure l. Flowchart of cohort assembly.
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on whether the variables were normally distributed, and cat-
egorical variables were compared using two-sided chi square 
tests. Characteristics between patients prescribed or not pre-
scribed ezetimibe are compared using the same methods. 
Odds ratios were calculated using logistic regression and 
95% confidence intervals. Logistic regression modeling was 
done to determine whether measured variables predicted if a 
patient had greater odds of being prescribed ezetimibe, and 
stepwise logistic regression was used to determine the opti-
mal model. Odds of mortality were then calculated for each 
variable using logistic regression. All variables were put into 
a full model to control for confounding, and stepwise regres-
sion was used to determine the optimal model Statistical 
analysis of the data was performed using SAS version 9.1.3 
(SAS Inc, North Carolina, USA). Statistical significance was 
considered present when P < 0.05.
The authors of this manuscript have certified that they 
comply with the Principles of Ethical Publishing in the Inter-
Table 1. Characteristics of Ezetimibe Plus Statin Versus Statin Only Patients
ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; CABG: 
coronary artery bypass graft; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; 
PCI: percutaneous coronary intervention.
Characteristic Statin and Ezetimibe (n = 918) Statin only (n = 2,909) P-value
Gender (Male) 517 (56%) 1,596 (55%) 0.447
Age 62.1 ± 11.5 63.6 ± 12.3 0.001
BMI 31.5 ± 6.9 31.2 ± 7.6 0.413
Weight 203.7 ± 50.8 200.7 ± 51.3 0.119
History of Tobacco use 517 (56%) 1,636 (56%) 0.970
Cholesterol 170.1 ± 62.3 169.6 ± 46.3 0.785
LDL-C 96.2 ± 42.1 96.6 ± 40.3 0.116
HDL-C 47.1 ± 13.3 48.2 ± 14.4 0.050
Hypertension 600 (65%) 2,051 (71%) 0.004
Coronary Artery Disease 405 (44%) 1,027 (35%) < 0.001
Diabetes 250 (27%) 838 (29%) 0.378
Myocardial Infarction 47 (5%) 160 (6%) 0.738
CABG 60 (7%) 131 (5%) 0.019
PCI 91 (10%) 245 (8%) 0.181
Cerebrovascular Accident 42 (5%) 161 (6%) 0.273
Transient Ischemia Attack 34 (4%) 120 (4%) 0.630
Death 35 (4%) 117 (4%) 0.652
Beta-blocker 605 (66%) 1,838 (63%) 0.145
ACE-I 473 (52%) 1,584 (54%) 0.129
ARB 185 (20%) 547 (19%) 0.361
Omega-3 378 (41%) 935 (32%) < 0.001
Aspirin 722 (79%) 2,165 (74%) 0.009
Diuretic 411 (45%) 1,319 (45%) 0.790
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national Journal of Cardiology [11].
 
Results
There were some significant differences between the groups 
(Table 1). The ezetimibe plus statin group was younger (P < 
0.001) and had lower HDL-C levels (P = 0.050) with higher 
incidence of coronary artery disease (P < 0.001) and CABG 
procedures (P = 0.019) in comparison to the statin only 
group. Hypertension was more prevalent in the statin-only 
group (P = 0.004). There was no difference between the total 
cholesterol (P = 0.785) or LDL (P = 0.116) between the two 
groups at baseline.
Logistic regression was used to determine whether cer-
tain characteristics increased the odds of a patient being pre-
scribed ezetimibe (Table 2). Using stepwise regression, three 
variables significantly changed the odds. Patients with high-
er HDL levels had lower odds of being on ezetimibe in ad-
dition to a statin. Patients diagnosed with hypertension were 
19.5% less likely to be on both medications, and those taking 
omega-3 were 69% more likely to be taking ezetimibe.
The odds of mortality based on the measured demo-
graphic variables, cholesterol levels, disease diagnoses, 
cardiovascular procedures, and cardiovascular medications 
were each calculated independently using logistic regression 
(Table 3). No survival advantage was seen with ezetimibe 
added to a statin (4% in both groups). When controlling for 
all measured factors, advancing age, a history of smoking, 
hypertension, a lower HDL level, having diabetes, taking 
beta-blockers, taking diuretics, and not taking omega-3 fatty 
acids were all significantly associated with mortality. Ezet-
imibe dropped out of the final model and was then added 
back to find a final odds ratio. As could be predicted from 
looking at Table 1, a patient who takes both ezetimibe and 
statins was not found to benefit with regard to all cause mor-
tality from a patient taking only statins (OR 1.067, 95% CI: 
0.713 - 1.598). Omega-3 fatty acid use (OR 0.554, 95% CI: 
0.373 - 0.823) or a higher HDL-C (OR 0.974, 95% CI: 0.959 




This study adds to the growing body of evidence that ezeti-
mibe may not provide substantial outcomes benefit in the 
treatment of hyperlipidemia. Our data indicate that there is 
no apparent mortality benefit for ezetimibe over mid-term 
follow up after one to three years of use.
Two trials where ezetimibe has been shown to have 
clinical efficacy are the SEARS and the SHARP trial. In the 
SEAS trial (Simvastatin and Ezetimibe in Aortic Stenosis) 
which compared patients on simvastatin 40 mg and ezeti-
mibe 10 mg to those on placebo, fatal and nonfatal myocar-
dial infarctions were significantly reduced with associated 
reductions in LDL-C. The SHARP trial demonstrated a 17% 
reduction in major atherosclerotic events. However, both 
these trials involve use of a statin and ezetimibe in compari-
son with a placebo and the observed clinical benefits could be 
due to the statin alone [9, 10]. In contrast our study compares 
the mortality benefit in patients taking statin and ezetimibe 
against those taking statin alone. To our knowledge ours is 
the first study that attempts to look at the clinical efficacy of 
ezetimibe in comparison to a statin alone and demonstrated 
no additive benefit for using ezetimibe.
Ezetimibe works by inhibiting the cholesterol absorp-
tion in the jejunum while statins work by inhibiting choles-
terol synthesis by inhibiting the enzyme HMG CoA reduc-
tase [12]. Reduced hepatic synthesis of LDL-C by the statins 
results in up regulation of hepatic LDL receptors and conse-
quent increase in uptake of LDL-C from the blood resulting 
in reduced serum LDL levels [13]. However, these effects 
also result in enhanced cholesterol absorption. Thus ezeti-
mibe which acts by inhibiting cholesterol absorption in the 
jejunum is supposed to have a complementary mechanism 
of action to that of the statins and the combination has been 
shown to achieve LDL-C reductions that have not been pos-
sible with statin monotherapy alone. However, these reduc-
tions in LDL-C have failed to demonstrate clinical benefits 
as seen in the ENHANCE and the ARBITER 6 HALTS tri-
als [5, 8]. Thus the randomized control trial (IMPROVE IT) 
which is testing clinical events in acute coronary syndrome 
patients on ezetimibe in addition to intensive statin treatment 
Table 2. Odds of Being Prescribed Ezetimibe
HDL-C: high density lipoprotein cholesterol.
Characteristic Unadjusted Odds Ratio Stepwise Model
HDL-C 0.994 (0.989 - 0.999) 0.992 (0.985 - 1.000)
Hypertension 0.805 (0.705 - 0.919) 0.758 (0.609 - 0.942)
Omega-3 fatty acids 1.689 (1.483 - 1.923) 1.457 (1.178 - 1.802)
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is highly anticipated.
Limitations: Though this study indicates a lack of clini-
cal efficacy for ezetimibe, it does face several limitations. 
Despite the large sample size, the data only comes from one 
group of cardiologists at one medical center and is retro-
spective. Our study did not include lipid values following 
administration of ezetimibe. Thus the benefits of LDL reduc-
tion could not be demonstrated in our study. However the 
primary aim was to look at the clinical endpoint of mortality 
as LDL reduction by ezetimibe has already been well estab-
Table 3. Odds of Mortality Based on Cardiovascular Risk Factors
ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body mass index; CABG: coronary 
artery bypass graft; CVA: cerebrovascular accident; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipopro-
tein cholesterol; PCI: percutaneous coronary intervention; TIA: transient ischemia attack; *Hypertension was added back into 
the model to control confounding; **Ezetimibe was added back into the stepwise model because it drops out. P values < 0.05 
for all odds ratios by stepwise model except * and **.
Characteristic Unadjusted Odds Ratio Adjusted Odds Ratio Stepwise Model
Gender (Male) 1.329 (0.952 - 1.856) 1.041 (0.672 - 1.613) -
Age 1.063 (1.046 - 1.080) 1.066 (1.050 - 1.083) 1.059 (1.042 - 1.077)
BMI 0.993 (0.953 - 1.034) 0.979 (0.933 - 1.026) -
Weight 0.995 (0.989 - 1.001) 0.999 (0.992 - 1.007) -
History of Smoking 1.956 (1.370 - 2.794) 1.929 (1.337 - 2.784) 1.884 (1.303 - 2.725)
Cholesterol 0.992 (0.986 - 0.997) 0.995 (0.989 - 1.001) -
LDL-C 1.004 (0.999 - 1.009) 1.006 (1.001 - 1.010) 1.005 (1.001 - 1.010)
HDL-C 0.969 (0.955 - 0.984) 0.976 (0.960 - 0.992) 0.974 (0.959 - 0.989)
Hypertension 1.057 (0.741 - 1.508) 0.643 (0.435 - 0.951) 0.840 (0.583 - 1.211)*
Coronary Artery Disease 2.074 (1.497 - 2.874) 1.308 (0.878 - 1.948) -
Diabetes 2.490 (1.797 - 3.450) 2.319 (1.653 - 3.252) 2.535 (1.773 - 3.624)
Myocardial Infarction 1.105 (0.555 - 2.200) 0.858 (0.412 - 1.788) -
CABG 3.719 (1.624 - 4.552) 1.501 (0.847 - 2.659) -
PCI 0.971 (0.544 - 1.733) 0.844 (0.448 - 1.591) -
CVA 3.194 (1.281 - 3.760) 1.197 (0.673 - 2.126) -
TIA 1.737 (0.890 - 3.350) 1.536 (0.767 - 3.077) -
Beta-blocker 2.274 (1.524 - 3.394) 1.676 (1.109 - 2.535) 1.625 (1.064 - 2.482)
ACE-I 1.543 (1.102 - 2.162) 1.040 (0.712 - 1.519) -
ARB 1.328 (0.906 - 1.948) 1.149 (0.760 - 1.737) -
Omega-3 0.561 (0.382 - 0.823) 0.547 (0.369 - 0.811) 0.554 (0.373 - 0.823)
Aspirin 1.231 (0.827 - 1.830) 0.841 (0.546 - 1.295) -
Diuretic 2.020 (1.447 - 2.820) 1.407 (0.961 - 2.059) 1.461 (1.011 - 2.112)
Ezetimibe 0.946 (0.644 - 1.390) 1.093 (0.733 - 1.628) 1.067 (0.713 - 
1.598)**
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lished.
Conclusion
No significant mortality benefit was found with the use of 
ezetimibe in combination with a statin. Further randomized 
trials investigating the clinical efficacy of ezetimibe in the 
general population are needed.
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